Research programme: antibody-based cancer therapeutics - MabSpace Biosciences

Drug Profile

Research programme: antibody-based cancer therapeutics - MabSpace Biosciences

Alternative Names: MSB 2311

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MabSpace Biosciences
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Feb 2018 MabSpace Biosciences plans a first-in-human trial for MSB 2311 in Solid tumours (Late-stage disease, Metastatic disease) in China/USA
  • 16 Feb 2018 US FDA approves IND application for MSB 2311 in Solid tumours (9234287; 9234082)
  • 25 Oct 2017 MabSpace Biosciences announces intention to submit an IND to the US FDA for MSB 2311 in Cancer in December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top